Pfizer Inc (PFE) 28.82 $PFE
Most active New York Stock Exchange-traded stocks
AP - Thu Aug 21, 5:08PM CDT
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:
Final Glance: Pharmaceuticals companies
AP - Thu Aug 21, 5:08PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
Astellas-Basilea's Isavuconazole Accepted for EU Review - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 21, 4:30PM CDT
Astellas Pharma, Inc. (ALPMY) and Basilea's isavuconazole has been accepted for review in the EU for the treatment of invasive aspergillosis and mucormycosis.
FDA clears Eliquis for new use against blood clots
AP - Thu Aug 21, 2:10PM CDT
WASHINGTON (AP) — Bristol-Myers Squibb and Pfizer said Thursday that federal regulators have expanded approval of their blood thinner Eliquis to treat two types of dangerous blood clots.
Contract Researcher Parexel Sees Growth In Biotech
at Investor's Business Daily - Thu Aug 21, 2:00PM CDT
When it comes to procuring clinical research services, small biotechs are like the average Janes and Joes who must wait in line to enter a nightclub while celebrities are whisked in like royalty the second they show up. In this case, the celebrities...
U.S. FDA Approves Eliquis (apixaban) for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and for the Reduction in the Risk of Recurrent DVT and PE Following Initial Therapy
Business Wire - Thu Aug 21, 12:31PM CDT
--Eliquis demonstrated superiority in the primary safety endpoint of major bleeding versus enoxaparin/warfarin in the AMPLIFY trial
Midday Glance: Pharmaceuticals companies
AP - Thu Aug 21, 12:22PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Video: Illumina Partners With Big Pharma Firms
at Investor's Business Daily - Thu Aug 21, 11:03AM CDT
Illumina (ILMN), a maker of DNA sequencing products, said Thursday that it has struck strategic partnerships with several big drugmakers to develop what it calls a universal next-generation sequencing-based oncology test system for cancer diagnosis....
Why AstraZeneca (AZN) Stock Is Higher Today
at The Street - Thu Aug 21, 8:35AM CDT
A renewed takeover attempt by Pfizer (PFE) for AstraZeneca (AZN) may come at year's end.
Lilly psoriasis drug fares well in late-stage test
AP - Thu Aug 21, 7:55AM CDT
INDIANAPOLIS (AP) — Drugmaker Eli Lilly and Co. said its potential psoriasis treatment fared better than both a fake drug and a competitor's product during late-stage testing on patients with the most common form of the skin disease.
Palbociclib Expanded Access Program Now Open To Eligible U.S. Patients With HR+, HER2- Advanced Breast Cancer
Business Wire - Thu Aug 21, 7:01AM CDT
Pfizer Inc. today announced that the company has initiated a multi-center, open-label expanded access program (EAP) in the United States for the investigational CDK 4/6 inhibitor, palbociclib. Through the program, palbociclib is being made available for use in combination with letrozole for post-menopausal women with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer for whom letrozole is considered appropriate therapy. Healthcare professionals and patients can learn more about the palbociclib EAP by visiting www.clinicaltrials.gov (trial number: NCT02142868).
Healthcare Enjoys Growth Trends: 3 Medical Stocks to Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 20, 3:27PM CDT
Favorable industry trends in the pharma and bio-tech space makes the healthcare sector a lucrative investment destination.
Baxter International Expands Dialyzers Facility in Alabama - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 20, 2:10PM CDT
Baxter International (BAX) has been experiencing burgeoning demand for dialyzers across the globe as more people are getting inflicted by ESRD
Early Glance: Pharmaceuticals companies
AP - Wed Aug 20, 11:22AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Expanding IBD Research Through Collaboration
PR Newswire - Wed Aug 20, 8:00AM CDT
The Crohn's & Colitis Foundation of America (CCFA) announces an agreement with Pfizer Inc.'s Centers for Therapeutic Innovation (CTI) to identify and support the potential development and translation of research in the area of inflammatory bowel disease (IBD). Capitalizing on CCFA's expertise in the field of IBD research and CTI's network of academic medical centers, the organizations will collaborate to drive promising translational research projects toward the clinic. The collaboration will initially involve the co-funding of research projects that focus on studying validated targets in Crohn's Disease and ulcerative colitis, which are the two most common types of IBD. This alliance represents CCFA's first-ever joint funding agreement with a pharmaceutical company.
Bristol-Myers Squibb and Pfizer to Present New Data on Eliquis(R) (apixaban) at the ESC Congress 2014
Business Wire - Wed Aug 20, 7:00AM CDT
--New global health economics and outcomes research (GHEOR) assessing Eliquis cost effectiveness and real-world comparative effectiveness research will also be presented
Most active New York Stock Exchange-traded stocks
AP - Thu Aug 21, 5:08PM CDT
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:
Final Glance: Pharmaceuticals companies
AP - Thu Aug 21, 5:08PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
Astellas-Basilea's Isavuconazole Accepted for EU Review - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 21, 4:30PM CDT
Astellas Pharma, Inc. (ALPMY) and Basilea's isavuconazole has been accepted for review in the EU for the treatment of invasive aspergillosis and mucormycosis.
FDA clears Eliquis for new use against blood clots
AP - Thu Aug 21, 2:10PM CDT
WASHINGTON (AP) — Bristol-Myers Squibb and Pfizer said Thursday that federal regulators have expanded approval of their blood thinner Eliquis to treat two types of dangerous blood clots.
Contract Researcher Parexel Sees Growth In Biotech
at Investor's Business Daily - Thu Aug 21, 2:00PM CDT
When it comes to procuring clinical research services, small biotechs are like the average Janes and Joes who must wait in line to enter a nightclub while celebrities are whisked in like royalty the second they show up. In this case, the celebrities...
U.S. FDA Approves Eliquis (apixaban) for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and for the Reduction in the Risk of Recurrent DVT and PE Following Initial Therapy
Business Wire - Thu Aug 21, 12:31PM CDT
--Eliquis demonstrated superiority in the primary safety endpoint of major bleeding versus enoxaparin/warfarin in the AMPLIFY trial
Midday Glance: Pharmaceuticals companies
AP - Thu Aug 21, 12:22PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Video: Illumina Partners With Big Pharma Firms
at Investor's Business Daily - Thu Aug 21, 11:03AM CDT
Illumina (ILMN), a maker of DNA sequencing products, said Thursday that it has struck strategic partnerships with several big drugmakers to develop what it calls a universal next-generation sequencing-based oncology test system for cancer diagnosis....
Why AstraZeneca (AZN) Stock Is Higher Today
at The Street - Thu Aug 21, 8:35AM CDT
A renewed takeover attempt by Pfizer (PFE) for AstraZeneca (AZN) may come at year's end.
Lilly psoriasis drug fares well in late-stage test
AP - Thu Aug 21, 7:55AM CDT
INDIANAPOLIS (AP) — Drugmaker Eli Lilly and Co. said its potential psoriasis treatment fared better than both a fake drug and a competitor's product during late-stage testing on patients with the most common form of the skin disease.
Palbociclib Expanded Access Program Now Open To Eligible U.S. Patients With HR+, HER2- Advanced Breast Cancer
Business Wire - Thu Aug 21, 7:01AM CDT
Pfizer Inc. today announced that the company has initiated a multi-center, open-label expanded access program (EAP) in the United States for the investigational CDK 4/6 inhibitor, palbociclib. Through the program, palbociclib is being made available for use in combination with letrozole for post-menopausal women with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer for whom letrozole is considered appropriate therapy. Healthcare professionals and patients can learn more about the palbociclib EAP by visiting www.clinicaltrials.gov (trial number: NCT02142868).
Healthcare Enjoys Growth Trends: 3 Medical Stocks to Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 20, 3:27PM CDT
Favorable industry trends in the pharma and bio-tech space makes the healthcare sector a lucrative investment destination.
Baxter International Expands Dialyzers Facility in Alabama - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 20, 2:10PM CDT
Baxter International (BAX) has been experiencing burgeoning demand for dialyzers across the globe as more people are getting inflicted by ESRD
Early Glance: Pharmaceuticals companies
AP - Wed Aug 20, 11:22AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Expanding IBD Research Through Collaboration
PR Newswire - Wed Aug 20, 8:00AM CDT
The Crohn's & Colitis Foundation of America (CCFA) announces an agreement with Pfizer Inc.'s Centers for Therapeutic Innovation (CTI) to identify and support the potential development and translation of research in the area of inflammatory bowel disease (IBD). Capitalizing on CCFA's expertise in the field of IBD research and CTI's network of academic medical centers, the organizations will collaborate to drive promising translational research projects toward the clinic. The collaboration will initially involve the co-funding of research projects that focus on studying validated targets in Crohn's Disease and ulcerative colitis, which are the two most common types of IBD. This alliance represents CCFA's first-ever joint funding agreement with a pharmaceutical company.
Bristol-Myers Squibb and Pfizer to Present New Data on Eliquis(R) (apixaban) at the ESC Congress 2014
Business Wire - Wed Aug 20, 7:00AM CDT
--New global health economics and outcomes research (GHEOR) assessing Eliquis cost effectiveness and real-world comparative effectiveness research will also be presented
